BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36451674)

  • 1. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.
    Cho H; Kim JE; Hong YS; Kim SY; Kim J; Ryu YM; Kim SY; Kim TW
    Oncoimmunology; 2022; 11(1):2148374. PubMed ID: 36451674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
    Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
    Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
    Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.
    Tojo M; Horie H; Koinuma K; Miyato H; Tsukui H; Kaneko Y; Futoh Y; Kimura Y; Takahashi K; Saito A; Ohzawa H; Yamaguchi H; Lefor AK; Sata N; Kitayama J
    Colorectal Dis; 2022 Oct; 24(10):1140-1149. PubMed ID: 35502766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of neoadjuvant chemoradiotherapy on infiltrating immune cells in the tumor microenvironment of rectal cancer].
    Yang Q; Zhou C; Han C; Zhang Y; Jiang Y; Li Z; Ma J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(8):1270-1276. PubMed ID: 34549721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
    Bando H; Tsukada Y; Inamori K; Togashi Y; Koyama S; Kotani D; Fukuoka S; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Wakabayashi M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Suzuki Y; Sato A; Nishikawa H; Ito M; Yoshino T
    Clin Cancer Res; 2022 Mar; 28(6):1136-1146. PubMed ID: 35063964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
    Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
    Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
    Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer.
    Hong SW; Lee S; Kim YJ; Ahn S; Park IJ; Hong SM; Hwang SW; Park SH; Yang DH; Ye BD; Byeon JS; Yang SK; Kim J; Kim SY; Myung SJ
    J Gastroenterol Hepatol; 2022 Mar; 37(3):542-550. PubMed ID: 34993983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer.
    Lin J; Peng J; Qdaisat A; Li L; Chen G; Lu Z; Wu X; Gao Y; Zeng Z; Ding P; Pan Z
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2551-2560. PubMed ID: 27613188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
    Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Mediators CD8
    Zaghloul H; Abbas A; Abdulah D
    J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
    Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
    Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer.
    Lee IH; Hwang S; Lee SJ; Kang BW; Baek D; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Cho SH; Kim JG
    Anticancer Res; 2017 Mar; 37(3):1459-1465. PubMed ID: 28314318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients.
    Yasui K; Kondou R; Iizuka A; Miyata H; Tanaka E; Ashizawa T; Nagashima T; Ohshima K; Urakami K; Kusuhara M; Muramatsu K; Sugino T; Yamguchi K; Mori K; Harada H; Nishimura T; Kagawa H; Yamakawa Y; Hino H; Shiomi A; Akiyama Y
    J Radiat Res; 2020 Sep; 61(5):766-775. PubMed ID: 32672335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.